Close Menu

NEW YORK – A significant proportion of non-small cell lung cancer patients being evaluated through the Veterans Health Administration's National Precision Oncology Program (NPOP) are not prescribed targeted therapies for actionable variants in their tumors, new research suggests.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.